Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"LG Chem","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LG Chem Life Sciences Innovation Center Announces Data from Phase I Study of its Ulcerative Colitis Treatment LC51-0255","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"LG Chem"},{"company":"Bridge Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bridge Biotherapeutics Holds a Company Briefing on the Development of New Drug Candidates for Ulcerative Colitis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Bridge Biotherapeutics"},{"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"},{"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"},{"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The EASL 2021","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"},{"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"},{"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"},{"company":"Enzychem Lifesciences Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase II","country":"SOUTH KOREA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Enzychem Lifesciences Corporation"}]

Enzychem Lifesciences Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting

Details:

EC-18 (mosedipimod) is immune modulator, has unique MOA called PETA which accelerates PRR-mediated endocytosis, endosome formation, ROS generation and recycle of PRR such TLR4 so that EC-18 duration of inflammatory immune response by removing PAMP associated danger signals.

Lead Product(s): Mosedipimod

Therapeutic Area: Gastroenterology Product Name: EC-18

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 25, 2022

ASK
US

Upload
your Pipeline Activity

Enzychem Lifesciences Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enzychem Lifesciences Announces Poster Presentation of EC-18 Abstract at the ASCO 2022 Annual Meeting

Details:

The primary efficacy endpoint demonstrated that the median duration of SOM (defined as WHO Grades 3 or 4) from baseline through short-term follow-up period (STFU) was 0.0 days in the EC-18 group versus 13.5 days in the placebo group (100% reduction).

Lead Product(s): Mosedipimod

Therapeutic Area: Gastroenterology Product Name: EC-18

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 06, 2022

ASK
US

Upload
your Pipeline Activity

Enzychem Lifesciences Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enzychem Files for FDA Breakthrough Therapy Designation for EC-18 for the Treatment of Chemoradiation-Induced Oral Mucositis

Details:

EC-18 is in clinical development in Phase 2 clinical trials in chemoradiation-induced oral mucositis and COVID-19. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.

Lead Product(s): Mosedipimod

Therapeutic Area: Gastroenterology Product Name: EC-18

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 08, 2021

ASK
US

Upload
your Pipeline Activity

Enzychem Lifesciences Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enzychem Lifesciences Announces Oral Presentation of TLR Signaling Inhibition with Mosedipimod (EC-18) at The EASL 2021

Details:

Poster titled "First in-class, orally active Toll-like receptor signaling inhibitor mosedipimod (PLAG) attenuates molecular, biochemical and histologic features of nonalcoholic steatohepatitis (NASH) in vitro and in vivo" will be presented at the EASL Congress 2021.

Lead Product(s): Mosedipimod

Therapeutic Area: Gastroenterology Product Name: EC-18

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2021

ASK
US

Upload
your Pipeline Activity

Enzychem Lifesciences Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enzychem Lifesciences to Present at the 2021 NASH-TAG Conference Highlighting TLR Signaling Inhibition with Mosedipimod (EC-18)

Details:

Poster titled Titled "TLR Signaling Inhibition with Mosedipimod" will be presented at the conference. EC-18 acts as an immunomodulator, facilitating the resolution of inflammation and early return to homeostasis.

Lead Product(s): Mosedipimod

Therapeutic Area: Gastroenterology Product Name: EC-18

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2021

ASK
US

Upload
your Pipeline Activity

Enzychem Lifesciences Corporation

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Enzychem Lifesciences Presenting at Biotech Showcase Digital 2021

Details:

At Biotech Showcase 2021, the company will provide a corporate update for its clinical programs, specifically its Phase 2 COVID-19 study and its Phase 2 clinical trial of EC-18 in Chemoradiation-induced Oral Mucositis, which will report results in the first half of this year.

Lead Product(s): Mosedipimod

Therapeutic Area: Gastroenterology Product Name: EC-18

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 08, 2021

ASK
US

Upload
your Pipeline Activity

Bridge Biotherapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Bridge Biotherapeutics Holds a Company Briefing on the Development of New Drug Candidates for Ulcerative Colitis

Details:

Company has confirmed both the safety and efficacy profiles of BBT-401 in active ulcerative colitis patients through the first cohort study of the Phase 2a trial.

Lead Product(s): BBT-401

Therapeutic Area: Gastroenterology Product Name: BBT-401

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 22, 2020

ASK
US

Upload
your Pipeline Activity

LG Chem

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

LG Chem Life Sciences Innovation Center Announces Data from Phase I Study of its Ulcerative Colitis Treatment LC51-0255

Details:

The ePoster highlighted the safety, pharmacokinetics and mechanistic properties of LC51-0255. A Phase II trial in patients with moderate to severely active ulcerative colitis is currently in development.

Lead Product(s): LC51-0255

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY